Report : Asia Pacific Platelet Rich Plasma Tube Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Usage (Skin Rejuvenation, Hair Restoration, Orthopedics, Surgical Oncology, Gynecology, and Others), Volume (Less Than 5 ML, 6 ML TO 10 ML, and More Than 10 ML), and End User (MedSpas, Dermatology Offices, Hospitals and Healthcare Practices, Tricologist Practices, and Others)
At 18.2% CAGR, the Asia Pacific Platelet Rich Plasma Tube Market is speculated to be worth US$ 213.81 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Asia Pacific platelet rich plasma tube market was valued at US$ 78.59 million in 2022 and is expected to reach US$ 213.81 million by 2028, registering a CAGR of 18.2% from 2022 to 2028. Rising number of cosmetic and aesthetic procedures and incorporation of platelet-rich plasma in regenerative medicine are the critical factors attributed to the Asia Pacific platelet rich plasma tube market expansion.
Platelet-rich plasma procedures utilize the body’s natural tissue repair process to achieve improved form and function. PRP procedure is intended for several noninvasive cosmetic skin treatments. It shows promising results in plastic surgery. In the aesthetic procedures, PRP is used to improve skin texture; add volume to the face, hands, and neck; treat fine lines and wrinkles around the eyes; minimize wrinkles and lines around the mouth; and treat acne scars and stretch marks. Characteristics of PRP such as ease of use, inexpensive to produce utilizing patient’s cells, and little or no risk of adverse reactions propel the adoption of PRP in treatments. According to a survey of the International Society of Aesthetic Plastic Surgery (ISAPS), ~10.1 million surgical procedures, including eyelid surgery, ear surgery, and Liposuction, and 14.4 million nonsurgical procedures such as hair removal, photo rejuvenation, and botulinum toxin were performed across the world in 2020. The program is the world's first comprehensive electronic medical tourism portal that offers medical packages comprising health, travel, hospitality, and visa services. The medical packages also cover wellness, cosmetic, orthopedic procedures, and specialized medical tests. The growing medical tourism and increasing medical packages support the growth of cosmetic and aesthetic procedures. As a result, the demand for PRP tubes is growing, which is driving the platelet rich plasma (PRP) tubes market growth.
On the contrary, high cost and adverse effects of platelet-rich plasma treatment hurdles the growth of Asia Pacific platelet rich plasma tube market.
Based on usage, the Asia Pacific platelet rich plasma tube market is segmented into skin rejuvenation, hair restoration, orthopedics, surgical oncology, gynecology, and others. The others segment held 24.6% share of Asia Pacific platelet rich plasma tube market in 2022, amassing US$ 19.42 million. It is projected to garner US$ 51.16 million by 2028 to expand at 17.5% CAGR during 2022–2028. The skin rejuvenation segment is further subsegmented into scars, skin aging, acne, skin ulcers, and others
Based on volume, the Asia Pacific platelet rich plasma tube market is segmented into less than 5 ml, 6ml to 10 ml, and more than 10 ml. The more than 10 ml segment held 61.8% share of Asia Pacific platelet rich plasma tube market in 2022, amassing US$ 48.61 million. It is projected to garner US$ 130.00 million by 2028 to expand at 17.8% CAGR during 2022–2028.
Based on end user, the Asia Pacific platelet rich plasma tube market is segmented into medspa, dermatology office, hospitals & healthcare practice, tricologist, and others. The hospitals & healthcare practice segment held 35.0% share of Asia Pacific platelet rich plasma tube market in 2022, amassing US$ 27.47 million. It is projected to garner US$ 74.35 million by 2028 to expand at 18.0% CAGR during 2022–2028.
Based on country, the Asia Pacific platelet rich plasma tube market has been categorized into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 32.0% share of Asia Pacific platelet rich plasma tube market in 2022. It was assessed at US$ 25.16 million in 2022 and is likely to hit US$ 70.15 million by 2028, exhibiting a CAGR of 18.6% during the forecast period.
Key players profiles in the Asia Pacific platelet rich plasma tube market report AdvaCare Pharma USA LLC; ADVIN HEALTH CARE; BIO-X; Henso Medical (Hangzhou) Co Ltd; Lingen Precision Medical Products Co Ltd; Manso Medical Co Ltd; and PROMED SOLUTIONS, among others.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: email@example.com